Spero Therapeutics Inc

NASDAQ:SPRO   10:21:02 AM EDT
13.49
-0.23 (-1.68%)
Products, Regulatory

Spero Therapeutics Announces The Initiation Of Bronchoalveolar Lavage And Renal Impairment Clinical Trials Of Spr206

Published: 06/15/2021 20:24 GMT
Spero Therapeutics Inc (SPRO) - Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of Spr206.
Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of Spr206.
Spero Therapeutics Inc - Phase 1 Bal Clinical Trial is an Open-label Study Designed to Enroll Thirty Healthy Volunteers Into Five Cohorts.